Brian Labadie to Humans
This is a "connection" page, showing publications Brian Labadie has written about Humans.
Connection Strength
0.185
-
Fojo AT, Labadie B. Harvesting information from Kaplan-Meier plots: part 1-detecting censoring. Oncologist. 2024 Jul 05; 29(7):551-553.
Score: 0.033
-
Labadie BW, Fojo AT. Requirements for Meaningful Progress in the Therapy of Neuroendocrine Cancers. JAMA Oncol. 2023 05 01; 9(5):606-608.
Score: 0.031
-
Labadie BW, Liu P, Bao R, Crist M, Fernandes R, Ferreira L, Graupner S, Poklepovic AS, Duran I, Maleki Vareki S, Balar AV, Luke JJ. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. J Transl Med. 2019 11 25; 17(1):386.
Score: 0.024
-
Labadie BW, Bao R, Luke JJ. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis. Clin Cancer Res. 2019 03 01; 25(5):1462-1471.
Score: 0.023
-
Labadie B, Patel RM, Gandy Labadie J, Hwang C, Okhunov Z, Landman J. Assessing the Effect of an Intensive 2-Week Surgical Training and Innovation Program for High-School Students. J Surg Educ. 2017 Nov - Dec; 74(6):958-967.
Score: 0.021
-
Ehrlich MI, Labadie BW, Bates SE, Fojo T. Mitotane and the myth of 14 mg/L. Lancet Oncol. 2024 Jan; 25(1):12-15.
Score: 0.008
-
Chaudagar K, Hieromnimon HM, Kelley A, Labadie B, Shafran J, Rameshbabu S, Drovetsky C, Bynoe K, Solanki A, Markiewicz E, Fan X, Loda M, Patnaik A. Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis. Clin Cancer Res. 2023 12 01; 29(23):4930-4940.
Score: 0.008
-
Chaudagar K, Hieromnimon HM, Khurana R, Labadie B, Hirz T, Mei S, Hasan R, Shafran J, Kelley A, Apostolov E, Al-Eryani G, Harvey K, Rameshbabu S, Loyd M, Bynoe K, Drovetsky C, Solanki A, Markiewicz E, Zamora M, Fan X, Sch?rer S, Swarbrick A, Sykes DB, Patnaik A. Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer. Clin Cancer Res. 2023 05 15; 29(10):1952-1968.
Score: 0.008
-
Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 08 20; 39(24):2647-2655.
Score: 0.007
-
Bao R, Surriga O, Olson DJ, Allred JB, Strand CA, Zha Y, Carll T, Labadie BW, Bastos BR, Butler M, Hogg D, Musi E, Ambrosini G, Munster P, Schwartz GK, Luke JJ. Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target. Melanoma Res. 2021 02 01; 31(1):27-37.
Score: 0.007
-
Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg D, Munster PN, Schwartz GK. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res. 2020 02 15; 26(4):804-811.
Score: 0.006
-
Ankeny JS, Labadie B, Luke J, Hsueh E, Messina J, Zager JS. Review of diagnostic, prognostic, and predictive biomarkers in melanoma. Clin Exp Metastasis. 2018 08; 35(5-6):487-493.
Score: 0.005
-
Gandy J, Labadie B, Bierman D, Zachary C. Photodynamic Therapy Effectively Treats Actinic Keratoses Without Pre-Illumination Incubation Time. J Drugs Dermatol. 2017 Mar 01; 16(3):275-278.
Score: 0.005